Phase I study of mFOLFOX-6, bevacizumab, and mTOR inhibitor RAD001 as first-line treatment of metastatic colorectal cancer.

被引：1
|
作者：
Gilcrease, Glynn Weldon
Weis, John R.
Jones, Kimberly
Davis, Thaylon
Mitchell, Marlene
Davidson, Cynthia
Sharma, Sunil
机构：
[1] Univ Utah, Salt Lake City, UT USA
[2] Huntsman Canc Inst, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.600
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
600
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer
    Gilcrease, G. Weldon
    Stenehjem, David D.
    Wade, Mark L.
    Weis, John
    McGregor, Kimberly
    Whisenant, Jonathan
    Boucher, Kenneth M.
    Thorne, Kelli
    Orgain, Nicole
    Garrido-Laguna, Ignacio
    Sharma, Sunil
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (03) : 482 - 489
  • [2] Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first–line treatment of metastatic colorectal cancer
    G. Weldon Gilcrease
    David D. Stenehjem
    Mark L. Wade
    John Weis
    Kimberly McGregor
    Jonathan Whisenant
    Kenneth M. Boucher
    Kelli Thorne
    Nicole Orgain
    Ignacio Garrido-Laguna
    Sunil Sharma
    Investigational New Drugs, 2019, 37 : 482 - 489
  • [3] A Phase I Pilot Study of the Oral mTOR Inhibitor RAD001 in Combination with Capecitabine for Metastatic Breast Cancer.
    Chen, C. S.
    Chen, M. M.
    Imaoka, R. T.
    Svahn, T.
    Guardino, A. E.
    CANCER RESEARCH, 2009, 69 (24) : 860S - 860S
  • [4] The Comparison of mDCF and mFOLFOX-6 as First-Line Treatment in Metastatic Gastric Cancer
    Acikgoz, Yusuf
    Esen, Selin Akturk
    Ucar, Gokhan
    Dirikoc, Merve
    Ergun, Yakup
    Bal, Oznur
    Uncu, Dogan
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (05)
  • [5] Open label phase III study of arfolitixorin vs leucovorin in mFOLFOX-6 for first-line treatment of metastatic colorectal cancer: AGENT
    Tabernero, J.
    Prager, G.
    Stintzing, S.
    Lenz, H. J.
    Nygren, H. P.
    Papadimitriou, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer
    Bayoglu, Ibrahim Vedat
    Yildiz, Ibrahim
    Varol, Umut
    Cokmert, Suna
    Kucukzeybek, Yuksel
    Alacacioglu, Ahmet
    Demir, Lutfiye
    Dirican, Ahmet
    Akyol, Murat
    Yildiz, Yasar
    Tarhan, Mustafa Oktay
    JOURNAL OF BUON, 2015, 20 (02): : 460 - 467
  • [7] A Phase Ib Trial of Erlotinib, an EGFR Inhibitor, and Everolimus (RAD001), an mTOR Inhibitor, in Patients with Metastatic Breast Cancer.
    Mayer, I. A.
    Means-Powell, J.
    Shyr, Y.
    Arteaga, C. L.
    CANCER RESEARCH, 2009, 69 (24) : 677S - 677S
  • [8] Phase Ib Study of Drozitumab Combined with First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer
    Lima, Caio M. Rocha
    Bayraktar, Soley
    Flores, Aurea M.
    MacIntyre, Jessica
    Montero, Alberto
    Baranda, Joaquina C.
    Wallmark, John
    Portera, Chia
    Raja, Rajiv
    Stern, Howard
    Royer-Joo, Stephanie
    Amler, Lukas C.
    CANCER INVESTIGATION, 2012, 30 (10) : 727 - 731
  • [9] A randomized study of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 as first-line treatment for unresectable metastatic colorectal cancer
    Belhadef, S.
    Arab, A.
    Belmadi, M.
    Beninal, M.
    Bacha, N.
    Abdallah, R.
    Mechta, K.
    Dahmane, A.
    Mahfouf, H.
    Oukkal, M.
    Bouzid, K.
    Faraqun, S.
    Bentabak, K.
    Younes, S. Ait
    ANNALS OF ONCOLOGY, 2020, 31 : S92 - S92
  • [10] An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer
    Garcia-Carbonero, Rocio
    Rivera, Fernando
    Maurel, Joan
    Ayoub, Jean-Pierre M.
    Moore, Malcolm J.
    Cervantes, Andres
    Asmis, Timothy R.
    Schwartz, Jonathan D.
    Nasroulah, Federico
    Ballal, Shaila
    Tabernero, Josep
    ONCOLOGIST, 2014, 19 (04): : 350 - 351
12345